People with one form of the genetic blood disorder hemophilia now have a one-time treatment with a $3.5 million price tag. The U.S. Food and Drug Administration approved the new gene therapy Hemgenix on Nov. 22. Soon after, drugmaker CSL Behring revealed its cost. The company said its drug would ultimately reduce health care costs… read on > read on >



















